NASDAQ
No price data available for this timeframe.
Agios Pharmaceuticals, Inc. (AGIO) has a consensus Buy rating from 29 analysts with an average price target of $43.33, representing +36.1% upside from the current price of $31.84.
| Date | Analyst | Firm | Target | Price | Upside |
|---|---|---|---|---|---|
| Jun 15, 2026 | Emily Bodnar | H.C. Wainwright | $54.00 | $29.46 | +83.30% |
| Apr 30, 2026 | Unknown | Truist Financial | $36.00 | $28.05 | +28.34% |
| Apr 20, 2026 | Emily Bodnar | H.C. Wainwright | $50.00 | $26.93 | +85.66% |
| Feb 12, 2026 | Greg Renza | Truist Financial | $39.00 | $28.41 |
Jun 11, 2026 | Maintained | JP Morgan | Neutral | Neutral |
May 29, 2026 | Maintained | B of A Securities | Buy | Buy |
Apr 30, 2026 | Maintained | Truist Securities | Buy | Buy |
Apr 21, 2026 | Maintained | B of A Securities | Buy | Buy |
Apr 20, 2026 | Maintained | HC Wainwright & Co. | Buy | Buy |
| +37.25% |
| Dec 26, 2025 | Unknown | Leerink Partners | $40.00 | $29.17 | +37.13% |